loading
Dare Bioscience Inc stock is traded at $2.12, with a volume of 155.08K. It is up +0.95% in the last 24 hours and down -18.77% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$2.10
Open:
$2.09
24h Volume:
155.08K
Relative Volume:
0.11
Market Cap:
$19.14M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-6.2353
EPS:
-0.34
Net Cash Flow:
$-39.49M
1W Performance:
-3.64%
1M Performance:
-18.77%
6M Performance:
-33.12%
1Y Performance:
-38.01%
1-Day Range:
Value
$2.05
$2.175
1-Week Range:
Value
$2.00
$2.29
52-Week Range:
Value
$1.83
$9.19

Dare Bioscience Inc Stock (DARE) Company Profile

Name
Name
Dare Bioscience Inc
Name
Phone
858-926-7655
Name
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Name
Employee
23
Name
Twitter
@DareBioscience
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
DARE's Discussions on Twitter

Compare DARE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DARE
Dare Bioscience Inc
2.12 18.67M 0 -30.16M -39.49M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Dare Bioscience Inc Stock (DARE) Latest News

pulisher
Aug 19, 2025

Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada

Aug 18, 2025
pulisher
Aug 18, 2025

Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks

Aug 18, 2025
pulisher
Aug 18, 2025

Dare Bioscience risks Nasdaq delisting over market value - MSN

Aug 18, 2025
pulisher
Aug 17, 2025

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN

Aug 17, 2025
pulisher
Aug 15, 2025

Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Daré Bioscience Announces Q2 2025 Financial Results - TipRanks

Aug 15, 2025
pulisher
Aug 14, 2025

Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan

Aug 14, 2025
pulisher
Aug 08, 2025

Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - The Manila Times

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan

Aug 07, 2025
pulisher
Jul 30, 2025

Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times

Jul 29, 2025
pulisher
Jul 29, 2025

Revolutionary Female Viagra Cream DARE to PLAY Gets Major Launch Campaign Before Q4 Release - Stock Titan

Jul 29, 2025
pulisher
Jul 25, 2025

Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks

Jul 25, 2025
pulisher
Jul 23, 2025

Daré Bioscience Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan

Jul 21, 2025
pulisher
Jul 17, 2025

Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider

Jul 17, 2025
pulisher
Jul 16, 2025

Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize

Jul 15, 2025
pulisher
Jul 15, 2025

3 Penny Stocks to Watch Now, 7/15/25 - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl

Jul 14, 2025

Dare Bioscience Inc Stock (DARE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):